Research Peptide
Retatrutide 30MG
30mg per vial
$300.00
● In Stock
Dosage
High-dose 30 mg presentation of Retatrutide (LY3437943) for extended preclinical protocols requiring the GLP-1 / GIP / glucagon triple-agonist profile.
Purity
≥99.5%
Mol. Weight
4,196.64 g/mol
Amino Acid Sequence
39 amino acids (fatty-acid modified)
Storage
Store lyophilized peptide at -20°C in a sealed vial away from light and moisture. After reconstitution with bacteriostatic water, keep refrigerated at 2–8°C and use within 30 days. Do not freeze reconstituted solution.
Certificate of Analysis
View third-party lab report · LOT #NP-RETATR-26
The 30 mg vial packages the same LY3437943 triple-agonist molecule in a bulk presentation intended for extended dose-titration protocols, chronic-dosing studies, and multi-arm comparative research. Its ~6-day half-life supports once-weekly dosing across long protocols. Reported research benefits: dose-dependent body weight loss exceeding dual-agonist comparators, reduction of visceral adipose tissue and hepatic steatosis (MRI-PDFF studies show substantial liver-fat clearance), improved insulin sensitivity and fasting glucose, increased basal metabolic rate via glucagon-receptor thermogenic activity, favorable shifts in ApoB and triglycerides, and sustained appetite suppression across 24–48 week protocols.
Related Products
Tirzepatide 10MG
First-in-class dual GIP / GLP-1 receptor agonist.
BPC-157 10MG
Body Protection Compound — recovery & tissue repair peptide.
TB-500 10MG
Thymosin Beta-4 fragment — systemic recovery peptide.